Minh Duc Cao, Devika Ganesamoorthy, Alysha Elliott, Huihui Zhang, Matthew Cooper, Lachlan Coin
doi: http://dx.doi.org/10.1101/019356
Clinical pathogen sequencing has significant potential to drive informed treatment of patients with unknown bacterial infection. However, the lack of rapid sequencing technologies with concomitant analysis has impeded clinical adoption in infection diagnosis. Here we demonstrate that commercially-available Nanopore sequencing devices can identify bacterial species and strain information with less than one hour of sequencing time, initial drug-resistance profiles within 2 hours, and a complete resistance profile within 12 hours. We anticipate these devices and associated analysis methods may become useful clinical tools to guide appropriate therapy in time-critical clinical presentations such as bacteraemia and sepsis.